• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21797 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2006     The Netherlands Organisation for Health Research and Development (ZonMw) [Randomized trial on the effects of a psychogeriatric diagnostic day hospital]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Randomized trial of timing of delivery in early preterm fetal growth restriction based on early and late fetal Doppler venous changes versus cardiotocography. Acronym TRUFFLE = Trial of Umbilical and Fetal Flow in Europe]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Ramucirumab for advanced gastric or gastroesophageal junction cancer]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (NSCLC, combination with erlotinib) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (new therapeutic indication): benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (new therapeutic indication): benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (hepatocellular carcinoma) - Addendum to Commission A19-73]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab (colorectal cancer) - Addendum to Commission A16-10]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab - benefit assessment according to §35a Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ramucirumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Raltegravir for the treatment of human immunodeficiency virus infection]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Radium-223-dichloride - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Radium-223 dichloride (mCRPC) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2012     Andalusian Health Technology Assessment Area (AETSA) [Radiosurgery and stereotactic body radiation therapy. Efficacy, safety and efficiency in primary lung cancer and pulmonary oligometastases]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radionuclide therapy - 90Yttrium and 177Lutetium somatostatin analogues for the treatment of inoperable neuroendocrine tumors]
2000     Finnish Office for Health Care Technology Assessment (Finohta) [Radiology in Central Finland - a regional operational model for the 2000s]
2009     Committee for New Health Technology Assessment (CNHTA) [Radiofrequency(RF) ablation of high grade dysplastic nodule of the liver]
2009     Committee for New Health Technology Assessment (CNHTA) [Radiofrequency(RF) ablation of hepatocellular adenoma]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Radiofrequency-assisted surgery in inferior turbinate hypertrophy]
2018     Basque Office for Health Technology Assessment (OSTEBA) [Radiofrequency tonsil reduction]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Radiofrequency percutaneous nucleoplasty in disc disorders]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Radiofrequency denervation for chronic lumbar or cervical spine pain]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation of tumours of the lung and mediastinal lymph nodes]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation of tumors of the urogenital tract (renal cell carcinoma, prostate cancer, uterine leiomyoma)]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation of primary tumors of the gastrointestinal tract (colorectal and pancreatic cancer)]
2007     Andalusian Health Technology Assessment Area (AETSA) [Radiofrequency ablation of breast tumours]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation of bone tumors (osteoid-osteoma and osseus metastases]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Radiofrequency ablation in benign bone tumors]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Radiofrequency ablation for treatment of symptomatic uterine myomas]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation for the treatment of head and neck cancer]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation for the treatment of breast cancer]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation for the treatment of benign and malign nodules of endocrine organs (thyroid gland and adrenal gland]
2020     Canary Health Service [Radiofrequency ablation for metastatic spinal lesions]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Radiofrequency ablation for hepatocellular carcinoma and colorectal liver metastases]
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Radiofrequency ablation for Barrett´s esophagus with high-grade dysplasia or intramucosal cancer: a systematic review]
2009     Committee for New Health Technology Assessment (CNHTA) [Radiofrequency (RF) ablation of primary and secondary lung malignancy]
2010     Committee for New Health Technology Assessment (CNHTA) [Radioembolization]
2015     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Radical-7™ – non-invasive continuous monitoring of hemoglobin]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Radiation exposure by medical X-ray applications]
2006     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [R-COD Browser - Web-based software to determine the mortality in Germany from all causes of death according to ICD-10 within the period 1998-2003]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Quantitative electroencephalography]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [Quantifying COPD patients preferences for early assisted discharge and inpatient hospital care for COPD exacerbations: a discrete choice experiment]
2026     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Quality of sleep: Can taking melatonin as a dietary supplement, e.g. in the form of tablets, sprays or soft gums, help to improve sleep?]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Quality of mammographic screening programmes]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Quality of life of stroke patients and their caregivers. Prognosis and results of rehabilitating treatment]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Quality of life in patients operated of total knee or hip artroplasty in Catalonia]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Quality of haematological and oncological care in children]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Quality of care in oncology and its measurement ]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Quality indicators for primary care professionals and managers]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Quality control in intensity modulated radiotherapy]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Pyridostigmine with aminopyridines in myasthenia gravis or Lambert-Eaton myasthenic syndrome]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pulsed electromagnetic fields for bone healing disorders]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pulsed electromagnetic fields for bone healing disorders - Addendum to Commission E17-08]
2008     Committee for New Health Technology Assessment (CNHTA) [Pulsed dye laser surgery with flexible fiberlaryngoscope]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pulmonary thrombectomy using a disc retriever for pulmonary artery embolism]
2022     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Pulmonary rehabilitation in people with chronic obstructive pulmonary disease (a briefing note)]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Public policies for the coverage of continuous positive airway pressure devices for the treatment of obstructive sleep apnea]
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Psychotherapy - concepts, effect factors and a comparison of legal regulations in three German speaking countries]
2018     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Psychological treatments and psychosocial interventions in forensic psychiatry – a systematic review]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [Psychological treatment of personality disorders: a multi-centered randomised controlled trial on the (cost-)effectiveness of schema-focused therapy]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Psychological Treatment for Postpartum Depression]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Psychological aspects, women's views, and expectations regarding ultrasound during pregnancy]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Psycho- and sociotherapeutic interventions: Adults - Evidence report on the S3 guideline "Cannabis-related disorders"]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Psycho- and sociotherapeutic interventions: Adolescents - Evidence report on the S3 guideline "Cannabis-related disorders"]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [PSMA PET/CT staging in patients with prostate cancer biochemical recurrence]
2009     Committee for New Health Technology Assessment (CNHTA) [PRSS1 gene, Mutation[Sequencing]]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Proxy HRQL value measurement in Alzheimer's dementia]
2010     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Proton therapy]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Proton therapy in cancer treatment. Update]
2010     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Protein-sparing modified fast diet: efficacity, safety and clinical use - literature review]
2012     Andalusian Health Technology Assessment Area (AETSA) [Protease inhibitors (Boceprevir and telaprevir) in the treatment of chronic HCV infection: relative efficacy, safety and efficiency]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Prosthesis replacement in ankle osteoarthritis]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Prostate rectum spacing in prostate radiation therapy]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Prostate cancer screening with the PSA test]
2009     Committee for New Health Technology Assessment (CNHTA) [PROS1 exon deletion/duplication test[MLPA]]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Propranolol - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2011     Basque Office for Health Technology Assessment (OSTEBA) [Proposed health survey of the Basque Country for institutionalised population in nursing homes (ESCAV-IR). CAPV 2010]
2010     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Proposals and approaches for reporting study results using "number needed to treat" (NNT) as the effect measure]
2020     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Proposal for the organization of bariatric medicine for the territories of the integrated university health and social services network of Laval University]
2005     Basque Office for Health Technology Assessment (OSTEBA) [Proposal for a programme for the early detection of infant deafness in the Basque Autonomous Community]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Prophylaxis for thromboembolic disease with low molecular weight heparins in adult patients in home care]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Prompt therapy in patients with speech disorders]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Promoting mental well-being in children and adolescents]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Promising measures to reduce the use of avoidable obstetrical interventions with low-risk women]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Promising measures to reduce the use of a avoidable obstetrical interventions with low-risk women]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Prolotherapy in chronic musculoskeletal disorders]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Programs for preventing suicide and suicide attempt in children]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Prognostic value, clinical effectiveness and cost-effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Prognostic value, clinical effectiveness and cost-effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events]
2014     Andalusian Health Technology Assessment Area (AETSA) [Prognostic genomic tests in early breast cancer: MammaPrint® and Oncotype DX®]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Profile of individuals insured by the public prescription drug insurance plan who have received treatment for hepatitis C (HCV)]
2009     Gesundheit Osterreich GmbH (GOeG) [Professional dental prophylaxis]
2021     Austrian Institute for Health Technology Assessment (AIHTA) [Process and evaluation of digital health applications in the context of "symptom-checkers"]
2012     Haute Autorite de sante (HAS) [Procedures for symmetrisation of the contralateral breast following breast cancer surgery]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Procedures and criteria for the regulation of innovative non-medicinal technologies into the benefit catalogue of solidly financed health care insurances]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Procedures and criteria for the regulation of innovative non-medicinal technologies into the benefit catalogue of solidly financed health care insurances]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Procedure for lung volume reduction in severe lung emphysema]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Procalcitonin-guided antibiotic therapy for acute infections]
2022     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Procalcitonin assay for optimizing the use of antibiotics in the treatment of infections]